FDA Approved: ARIXTRA — Supplemental Application (Mylan Institutional LLC)

View source ↗

Summary

FDA approved a supplemental application for ARIXTRA (fondaparinux sodium) submitted by Mylan Institutional LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism

Drugs mentioned

• ARIXTRA (fondaparinux sodium)

Snippet

SUPPL AP for ARIXTRA (FONDAPARINUX SODIUM)